Human Breast Cancer (ER+/PR+/Her2-), (Invasive duct carcinoma) FFPE Sections

$139.99

Add to Wishlist
Add to Wishlist

Description

SKU# Organ Pathology Diagnosis Therapies (Chemotherapies
,radiation and Hormone) before Collection of Sample
Gender/Age (year) Tumor Area(%) Tumor Grade TMN/Stage ER,PR & HER2 IHC Data
HuPS-02017T Breast Invasive duct carcinoma No Female/68 55% III T1bM0N0 ER(15% +),
PR(35%+),
Her2 (-)

Slide Preparation

Human tissue was fixed in formalin immediately after excision and embedded in paraffin. The tissue sections were 5 µm in thickness and mounted each on positively charged glass slides.

Sections/slide

1 section on each slide

Slides/Package

5 slides per package

Applications

Histology stain, IHC/IF, RNA scope ISH, FISH/ISH and DNA/RNA isolation for NGS.

Storage Condition

Store at 2-8ºC

More Images

HuPs-02017T Human ER+PR+HER2- Breast Cancer, H&E, 4x
HuPs-02017T Human ER+PR+HER2- Breast Cancer, H&E, 10x
HuPs-02017T Human ER+PR+HER2- Breast Cancer, H&E, 20x

Product Data Sheet and Material Safety Data Sheet (MSDS) (PDF)

HuPS-02017T Data Sheet

FFPE Blocks & Sections-MSDS

 

 

Frequently Asked Questions

What tissue is in this product?

Human breast invasive duct carcinoma, from a 68-year-old female donor. The tumor is ER-positive, PR-positive, and Her2-negative, grade III, stage T1bM0N0, with 55% tumor area.

What does the IHC data on the page show?

ER 15% positive, PR 35% positive, and Her2 negative.

Was the donor treated before the sample was collected?

No. The page lists no chemotherapy, radiation, or hormone therapy before collection of the sample.

How were the sections prepared?

The tissue was fixed in formalin immediately after excision and embedded in paraffin. The sections are 5 µm thick and mounted one per positively charged glass slide. Store the slides at 2–8 °C.

How many slides come in one package?

5 slides per package, with 1 section on each slide.

What can these sections be used for?

Histology staining, IHC/IF, RNA scope ISH, FISH/ISH, and DNA/RNA isolation for next-generation sequencing (NGS).